The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4 DRI Nature Communications What are the recommended dosing regimens, safety monitoring, and clinical trial considerations for senolytic agents such as dasatinib + quercetin, navitoclax, fisetin, and FOXO4DRI? PDF) The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4 DRI Frontiers Senolytic Peptide FOXO4 DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes My FOXO4 DRI Journey, I started going down the longevity rabbit hole because I knew something deeper was happening inside my body than just getting older., Low energy. Slower recovery. Senolytics: charting a new course or enhancing existing anti tumor therapies? Cellular Oncology Springer Nature Link